Phase 1 trial 14-day pilot programme launched
MHRA launches a pilot programme aiming to deliver first regulatory assessments for qualifying low-risk Phase 1 trials within 14 calendar days.
What this means
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is launching a new, faster review process for certain low-risk early-stage drug trials. The agency's pilot program aims to give an initial regulatory decision within just 14 days for qualifying applications by the end of 2026. This move could make the UK a more attractive location for early research, potentially speeding up the start of new studies while maintaining safety standards.
From the source
Guidance
Clinical trials: Phase 1, 14-Day Pilot Programme
The pilot aims to deliver the first wave 1 regulatory assessment in 14 calendar days for qualifying applications by the end of 2026.
From: Medicines and Healthcare products Regulatory Agency
Published: 17 August 2026
Get emails about this page
Documents
Clinical trials: Phase 1, 14-Day Pilot Programme
HTML
Details
The pilot is a targeted MHRA initiative to speed up approvals for certain low-risk Phase 1 trials. The pilot aims to deliver the first wave 1 regulatory assessment in 14 calendar days for qualifying applications by the end of 2026.
This accelerated pathway was introduced in response to stakeholder and government calls for faster clinical trial start-ups, while using a controlled, evidence-based approach to maintain high safety and quality standards.
By piloting a two-week assessment timeline for suitable trials, the MHRA seeks to boost the UK’s competitiveness in early-phase research and encourage sponsors to run more Phase 1 studies in the UK.
Updates to this page
Published 17 August 2026
Sign up for emails or print this page
Get emails about this page
Print this page
Reproduced from MHRA News · view original · public domain or open-licensed government work